Your browser doesn't support javascript.
loading
High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response.
Mentzer, Alexander J; Dilthey, Alexander T; Pollard, Martin; Gurdasani, Deepti; Karakoc, Emre; Carstensen, Tommy; Muhwezi, Allan; Cutland, Clare; Diarra, Amidou; da Silva Antunes, Ricardo; Paul, Sinu; Smits, Gaby; Wareing, Susan; Kim, HwaRan; Pomilla, Cristina; Chong, Amanda Y; Brandt, Debora Y C; Nielsen, Rasmus; Neaves, Samuel; Timpson, Nicolas; Crinklaw, Austin; Lindestam Arlehamn, Cecilia S; Rautanen, Anna; Kizito, Dennison; Parks, Tom; Auckland, Kathryn; Elliott, Kate E; Mills, Tara; Ewer, Katie; Edwards, Nick; Fatumo, Segun; Webb, Emily; Peacock, Sarah; Jeffery, Katie; van der Klis, Fiona R M; Kaleebu, Pontiano; Vijayanand, Pandurangan; Peters, Bjorn; Sette, Alessandro; Cereb, Nezih; Sirima, Sodiomon; Madhi, Shabir A; Elliott, Alison M; McVean, Gil; Hill, Adrian V S; Sandhu, Manjinder S.
Afiliación
  • Mentzer AJ; Centre for Human Genetics, University of Oxford, Oxford, UK. alexander.mentzer@ndm.ox.ac.uk.
  • Dilthey AT; Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK. alexander.mentzer@ndm.ox.ac.uk.
  • Pollard M; Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Gurdasani D; Institute of Medical Microbiology and Hospital Hygiene, University Hospital of Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Karakoc E; Genome Informatics Section, Computational and Statistical Genomics Branch, National Human Genome Research Institute, Bethesda, MD, USA.
  • Carstensen T; Wellcome Sanger Institute, Cambridge, UK.
  • Muhwezi A; Wellcome Sanger Institute, Cambridge, UK.
  • Cutland C; Wellcome Sanger Institute, Cambridge, UK.
  • Diarra A; Wellcome Sanger Institute, Cambridge, UK.
  • da Silva Antunes R; Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
  • Paul S; South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
  • Smits G; Groupe de Recherche Action en Santé (GRAS) 06 BP 10248, Ouagadougou, Burkina Faso.
  • Wareing S; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Kim H; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Pomilla C; National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
  • Chong AY; Microbiology Department, John Radcliffe Hospital, Oxford University NHS Foundation Trust, Oxford, UK.
  • Brandt DYC; Histogenetics, New York, USA.
  • Nielsen R; Wellcome Sanger Institute, Cambridge, UK.
  • Neaves S; Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Timpson N; Department of Integrative Biology, University of California at Berkeley, California, CA, USA.
  • Crinklaw A; Department of Integrative Biology, University of California at Berkeley, California, CA, USA.
  • Lindestam Arlehamn CS; Avon Longitudinal Study of Parents and Children at University of Bristol, Bristol, UK.
  • Rautanen A; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Kizito D; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Parks T; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
  • Auckland K; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Elliott KE; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Mills T; Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Ewer K; Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
  • Edwards N; Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Fatumo S; Department of Infectious Disease, Imperial College London, London, UK.
  • Webb E; Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Peacock S; Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Jeffery K; Centre for Human Genetics, University of Oxford, Oxford, UK.
  • van der Klis FRM; The Jenner Institute, University of Oxford, Oxford, UK.
  • Kaleebu P; The Jenner Institute, University of Oxford, Oxford, UK.
  • Vijayanand P; Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
  • Peters B; The Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine London, London, UK.
  • Sette A; MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine London, London, UK.
  • Cereb N; Tissue Typing Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Sirima S; Microbiology Department, John Radcliffe Hospital, Oxford University NHS Foundation Trust, Oxford, UK.
  • Madhi SA; Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Elliott AM; National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
  • McVean G; Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
  • Hill AVS; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Sandhu MS; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Nat Med ; 30(5): 1384-1394, 2024 May.
Article en En | MEDLINE | ID: mdl-38740997
ABSTRACT
How human genetic variation contributes to vaccine effectiveness in infants is unclear, and data are limited on these relationships in populations with African ancestries. We undertook genetic analyses of vaccine antibody responses in infants from Uganda (n = 1391), Burkina Faso (n = 353) and South Africa (n = 755), identifying associations between human leukocyte antigen (HLA) and antibody response for five of eight tested antigens spanning pertussis, diphtheria and hepatitis B vaccines. In addition, through HLA typing 1,702 individuals from 11 populations of African ancestry derived predominantly from the 1000 Genomes Project, we constructed an imputation resource, fine-mapping class II HLA-DR and DQ associations explaining up to 10% of antibody response variance in our infant cohorts. We observed differences in the genetic architecture of pertussis antibody response between the cohorts with African ancestries and an independent cohort with European ancestry, but found no in silico evidence of differences in HLA peptide binding affinity or breadth. Using immune cell expression quantitative trait loci datasets derived from African-ancestry samples from the 1000 Genomes Project, we found evidence of differential HLA-DRB1 expression correlating with inferred protection from pertussis following vaccination. This work suggests that HLA-DRB1 expression may play a role in vaccine response and should be considered alongside peptide selection to improve vaccine design.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Cadenas HLA-DRB1 Límite: Female / Humans / Infant / Male País/Región como asunto: Africa Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Cadenas HLA-DRB1 Límite: Female / Humans / Infant / Male País/Región como asunto: Africa Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido